Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 1, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, specifically regarding the SmithKline Beecham Employee Benefit Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
The filing details share transactions executed on July 24, 2006, by the Administrators of the SmithKline Beecham Employee Benefit Trust on behalf of participants in the GlaxoSmithKline Bonus Investment Plan:
- Sale 1: 433 Ordinary shares sold at GBP 14.87 per share.
- Sale 2: 9,505 Ordinary shares sold at GBP 14.89 per share.
- Sale 3: 69 Ordinary shares sold at GBP 15.06 per share.
- Transfer: 619 Ordinary shares transferred from the Trust to a participant.
Director Mr. J S Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the disclosure of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total volume of shares sold (9,607) and transferred (619) on July 24, 2006.
- Confirm the average transaction price range of GBP 14.87 to GBP 15.06 per share.
- Note that these transactions were executed by the Employee Benefit Trust, not directly by the named director, though the director holds an interest in the fund.
- Confirm that this filing does not contain updated financial performance data for the company.